Molecules to treat type II diabetes discovered

Mumbai: Tata Group promoted, Advinus
Therapeutics, announced the discovery of a novel
molecule for treatment of type II diabetes - GKM -001.

It is the first Glucokinase modulator discovered
and developed in India.

The molecule is an activator of glucokinase; an enzyme
that regulates glucose balance and insulin secretion in the
body. GKM-001 is indigenously developed molecule and the
initial clinical trials have shown excellent results for both
safety and efficacy, the company said in a statement here.

"Considering past failures of other companies, our
discovery program primarily focused on identifying a molecule
that would be efficacious without causing hypoglycemia; a side
effect associated with most compounds developed for this
target," Advinus Therapeutics MD & CEO, Rashmi Barbhaiya said.

Recently completed Phase I data indicate that Advinus`
GKM - 001 is a liver selective molecule that has overcome the
biggest clinical challenge of hypoglycemia. GKM-001 is
differentiated from most other GK molecules in development due
to this novel mechanism of action, Barbhaiya said.

We are very proud that GKM-001 is 100 per cent Indian.
Advinus`s discovery team in Pune discovered the molecule and
entire pre-clinical development was carried out at our centre
in Bangalore, he said.

PTI

By continuing to use the site, you agree to the use of cookies. You can find out more by clicking this link

Close